Irinotecan Hydrochloride Injection

What This Irinotecan Shortage Record Means

The FDA Drug Shortages database lists this record for Irinotecan Hydrochloride Injection (brand: IRINOTECAN HYDROCHLORIDE) from Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) with a current status of To Be Discontinued. The affected dosage form is Injection, presented as Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Sep 26, 2025 and was last updated Sep 26, 2025. The FDA cites the following reason: Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals. There are 5 other current records in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.